Respirable low-density microparticles formed in situ from aerosolized brittle matrices

Pharmaceutical Research

Volumn 30, Issue 3, 2013, Pages 813-825

  Watts, Alan B ^a   Wang, Yi Bo ^a   Johnston, Keith P ^b   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

dry powder inhalation; low density particles; particle engineering; respirable powder

Indexed keywords

LACTOSE; MANNITOL; RAFFINOSE; TACROLIMUS;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER INHALER; EQUIPMENT DESIGN; FREEZING; HYDROPHILICITY; LIGHT SCATTERING; MATERIAL COATING; MATERIALS TESTING; MOISTURE; PARTICLE SIZE; PRIORITY JOURNAL; STATIC ELECTRICITY; THIN FILM FREEZING;

ADMINISTRATION, INHALATION; AEROSOLS; CARBOHYDRATES; DRY POWDER INHALERS; EXCIPIENTS; FREEZING; HUMANS; MANNITOL; PARTICLE SIZE; POROSITY; POWDERS; WATER;

EID: 84878860769     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0922-2     Document Type: Article

References (47)

1. Kling J. Inhaled insulin's last gasp? Nat Biotech. 2008;26:479-80.
2. Crowder TM, Rosati JA, Schroeder JD, Hickey AJ, Martonen TB. Fundamental effects of paritcle morphology on lung delivery: predictions of Stoke's Law and the particular relevance to dry powder inhaler formulation and development. Pharm Res. 2002;19:239-45.
3. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, et al. Large Porous Particles for Pulmonary Drug Delivery. Science. 1997;276:1868.
4. Geiser M, Casaulta M, Kupferschmid B, Schulz H, Semmler-Behnke M, Kreyling W. The Role of Macrophages in the Clearance of Inhaled Ultrafine Titanium Dioxide Particles. Am J Respir Cell Mol Biol. 2008;38:371-6.
5. Scarpelli EM. Physiology of the alveolar surface network. Comp Biochem Physiol A Mol Integr Physiol. 2003;135:39-104.
6. Tam JM, McConville JT, Robert O, Williams I, Johnston KP. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci. 2008;97:4915-33.
7. Engstrom J, Tam J, Miller M, Williams R, Johnston K. Templated Open Flocs of Nanorods for Enhanced Pulmonary Delivery with Pressurized Metered Dose Inhalers. Pharm Res. 2009;26:101-17.
8. Crisp MT, Tucker CJ, Rogers TL, Williams III RO, Johnston KP. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J Control Release. 2007;117:351-9.
9. Matteucci ME, Brettmann BK, Rogers TL, Elder EJ, Williams RO, Johnston KP. Design of Potent Amorphous Drug Nanoparticles for Rapid Generation of Highly Supersaturated Media. Mol Pharm. 2007;4:782-93.
10. Matteucci ME, Paguio JC, Miller MA. Williams Iii RO, and Johnston KP. Highly Supersaturated Solutions from Dissolution of Amorphous Itraconazole Microparticles at pH 6.8. Mol Pharm. 2009;6:375-85.
11. McConville J, Overhoff K, Sinswat P, Vaughn J, Frei B, Burgess D, et al. Targeted High Lung Concentrations of Itraconazole Using Nebulized Dispersions in a Murine Model. Pharm Res. 2006;23:901-11.
12. Sinswat P, Overhoff KA, McConville JT, Johnston KP, Williams III RO. Nebulization of nanoparticulate amorphous or crystalline tacrolimus - Single-dose pharmacokinetics study in mice. Eur J Pharm Biopharm. 2008;69:1057-66.
13. Vaughn JM, Wiederhold NP, McConville JT, Coalson JJ, Talbert RL, Burgess DS, et al. Williams Iii RO, and Peters JI. Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. Int J Pharm. 2007;338:219-24.
14. Chiou WL, Riegelman S. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J Pharm Sci. 1969;58:1505-10.
15. Yang JZ, Young AL, Chiang P-C, Thurston A, Pretzer DK. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci. 2008;97:4869-78.
16. Tsapis N, Bennett D, Jackson B, Weitz DA, and Edwards DA. Trojan particles: Large porous carriers of nanoparticles for drug delivery. 2002;99:12001-12005.
17. Velaga SP, Berger R, Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide. Pharm Res. 2002;19:1564-71.
18. Cheng YS, Marshall TC, Henderson RF, Newton GJ. Use of a jet mill for dispersing dry powder for inhalation studies. Am Ind Hyg Assoc J. 1985;46:449-54.
19. Chawla A, Taylor KMG, Newton JM, Holbrook P. Production of spray dried salbutamol sulfate for use in dry powder aerosol formulation. Int J Pharm. 1994;108:233-40.
20. Overhoff KA, Johnston KP, Tam J, Engstrom J, Williams III RO. Use of thin film freezing to enable drug delivery: a review. J Drug Deliv Sci Tech. 2009;19:89-98.
21. Engstrom J, Lai E, Ludher B, Chen B, Milner T, Williams R, et al. Formation of Stable Submicron Protein Particles by Thin Film Freezing. Pharm Res. 2008;25:1334-46.
22. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Delivery Rev. 1996;19:3-36.
23. Overhoff KA, Engstrom JD, Chen B, Scherzer BD, Milner TE, Johnston KP, et al. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur J Pharm Biopharm. 2007;65:57-67.
24. Marple VA, Olson BA, Santhanakrishnan K, Mitchell JP, Murray SC, Hudson-Curtis BL. Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part II: archival calibration. J Aerosol Med. 2003;16:301-24.
25. Mitchell JP. Practices of coating collection surfaces of cascade impactors: a survey of members of the european pharmaceutical aerosol group (EPAG). Drug Deliv Lung. 2003;14:75-8.
26. Akashi T, Nefuji T, Yoshida M, Hosoda J. Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography. J Pharm Biomed Anal. 1996;14:339-46.
27. Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, et al. Considerations for the Development and Practice of Cascade Impaction Testing, Including a Mass Balance Failure Investigation Tree. J Aerosol Med. 2003;16:235-47.
28. Berg E, Svensson JO, Asking L. Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med. 2007;20:97-104.
29. Dunbar C, Kataya A, Tiangbe T. Reducing bounce effects in the Andersen cascade impactor. Int J Pharm. 2005;301:25-32.
30. Kamiya A, Sakagami M, Hindle M, and Byron PR. Aerodynamic sizing of metered dose inhalers: An evaluation of the andersen and next generation pharmaceutical impactors and their USP methods. 2004;93:1828-1837.
31. Choi H-G, Lee B-J, Han J-H, Lee M-K, Park K-M, Yong CS, Rhee J-D, Kim Y-B, and Kim C-K. Terfenadine β-Cyclodextrin Inclusion Complex with Antihistaminic Activity Enhancement. 2001;27:857-862.
32. Overhoff K, McConville J, Yang W, Johnston K, Peters J, Williams R. Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res. 2008;25:167-75.
33. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams III RO. Targeted intestinal delivery of supesaturated itraconazole for improved oral absorption. Pharm Res. 2008;25:1450-9.
34. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm. 2008;361:177-88.
35. Birchall JC, Jones BE, Morrissey A, Jones BE. A Comparison of the Puncturing Properties of Gelatin and Hypromellose Capsules for Use in Dry Powder Inhalers. Drug Dev Ind Pharm. 2008;34:870-6.
36. Pilcer G, Sebti T, Amighi K. Formulation and Characterization of Lipid-Coated Tobramycin Particles for Dry Powder Inhalation. Pharm Res. 2006;23:931-40.
37. Berchane NS, Carson KH, Rice-Ficht AC, Andrews MJ. Effect of mean diameter and polydispersity of PLG microspheres on drug release: experiment and theory. Int J Pharm. 2007;337:118-26.
38. Kajiwara K, Franks F, Echlin P, Greer AL. Structural and dynamic properites of crystalline and amorphous phases in raffinose-water mixtrues. Pharm Res. 1999;16:1441-8.
39. Gohel MC. A review of co-processed directly compressible excipients. J Pharm Pharm Sci. 2005;8:76-93.
40. Young P, Sung A, Traini D, Kwok P, Chiou H, Chan H-K. Influence of Humidity on the Electrostatic Charge and Aerosol Performance of Dry Powder Inhaler Carrier based Systems. Pharm Res. 2007;24:963-70.
41. Hogan SE, Buckton G. Water sorption/desorption-near IR and calorimetric study of crystalline and amorphous raffinose. Int J Pharm. 2001;227:57-69.
42. Lechuga-Ballesteros D, Charan C, Stults CLM, Stevenson CL, Miller DP, Vehring R, et al. Trileucine Improves Aerosol Performance and Stability of Spray-Dried Powders for Inhalation. J Pharm Sci. 2007;97:287-302.
43. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery - a review. Pharmaceut Sci Tech Today. 2000;3:138-45.
44. Jennings T. Lyophilization: Introduction and basic priciples. Bcoa Raton: CRC Press LLC; 1999.
45. Gohel MC, Jogani PD, and Bariya SH. Development of Agglomerated Directly Compressible Diluent Consisting of Brittle and Ductile Materials. 2003;8:143-151.
46. te Booy MPWM, de Ruiter RA, de Meere ALJ. Evaluation of the Physical Stability of Freeze-Dried Sucrose-Containing Formulations by Differential Scanning Calorimetry. Pharm Res. 1992;9:109-14.
47. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. 1997;86:1-12.